Nano-biotechnology is an interdisciplinary field that combines nanotechnology and biotechnology to manipulate and study biological systems at the nanoscale. The application of nanotechnology has had a significant impact on the development and enhancement of biologics, which are complex drugs used to treat various diseases, including cancers, autoimmune disorders, and chronic illnesses.
Impact of Nanobiotechnology on Biologics
Enhanced Drug Delivery
Nanobiotechnology enables the design of nanoparticles that can target specific cells or tissues, improving the precision of drug delivery.
Nanoparticles are being engineered to release biologics in a controlled manner over time.
Improved Stability
Nanocarriers can protect delicate biologics from degradation, increasing their stability and shelf life.
Encapsulating biologics in nanoparticles can help reduce their immunogenicity.
Innovative Therapeutic Approaches
Nanobiotechnology allows for the co-delivery of biologics with other therapeutic agents (e.g., chemotherapeutics or gene therapies).
Nanoparticles are being developed to deliver gene-editing tools like CRISPR/Cas9 with higher precision.
Diagnostic and Theranostic Applications
Nanobiotechnology is also being used to develop highly sensitive diagnostic tools that aids in early diagnosis and better monitoring of diseases treated with biologics.
Combining therapeutic and diagnostic capabilities in a single nanoplatform.
Overcoming Drug Resistance
Nanocarriers can help biologics bypass biological barriers, such as the blood-brain barrier, and overcome drug resistance mechanisms in cancer cells.
Cost and Manufacturing Efficiency
Scalability: Advances in nanobiotechnology could potentially reduce the cost of manufacturing biologics by improving yield and reducing waste in production processes.
Streamlined Formulations: Nanobiotechnology can simplify biologic formulations, making them easier to produce, store, and administer.
US FDA’s take on Nanobiotechnology
The U.S. Food and Drug Administration (FDA) identifies the potential of nanobiotechnology to revolutionize various aspects of medicine, including drug development, diagnostics, and medical devices. The agency has issued several guidance documents to help industry navigate the regulatory landscape for nanotechnology. These documents provide recommendations on the characterization, safety assessment, and quality control of nanomaterials.
"Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology" (2014):This guidance outlines the factors the FDA considers when determining whether a product involves nanotechnology, such as the size of the material and its unique properties.
"Guidance for Industry: Safety of Nanomaterials in Cosmetic Products" (2012): Although focused on cosmetics, this guidance provides insights into how the FDA assesses the safety of nanomaterials, which can be applicable to other products as well.
There are more guiding documents that provides guidance on the application of nanotechnology in food products and drug delivery.
Nano-Biotechnology Market Size and Growth
The global nanobiotechnology market was valued at approximately $45 billion in 2023 and is projected to reach around $80 billion by 2030. This represents a compound annual growth rate (CAGR) of approximately 8% to 10% during the forecast period.
Prominent industry players leveraging nano-biotechnology
Amgen
Pipeline Focus: Amgen’s pipeline includes biologics for oncology, cardiovascular, and inflammatory diseases with focus on enhancing its biologics using nanoparticle-based delivery systems.
Notable Programs: Amgen is developing therapies targeting the KRAS mutation in cancer using nanotechnology to enhance delivery. And Amgen is advancing bispecific antibodies to treat lung cancer, with potential applications of nanotechnology to improve drug delivery.
Novartis
Pipeline Focus: Novartis focuses on gene therapies, CAR-T cell therapies, and biologics for oncology, cardiovascular, and ophthalmology using nanotechnology to optimize delivery and stability.
Notable Programs: Novartis is enhancing its CAR-T platform, Kymriah, using nanobiotechnology to improve delivery and reduce side effects.
Ophthalmic Biologics: Novartis is developing biologics for eye diseases, with nanoparticle-based formulations.
Pfizer
Pipeline Focus: Pfizer's pipeline includes biologics for infectious diseases, oncology, and inflammatory diseases using nanotechnology in mRNA vaccines formulations.
Notable Programs: mRNA Vaccines: Pfizer’s collaboration with BioNTech on mRNA vaccines is a key example of nanotechnology application, with lipid nanoparticles used for delivery.
Roche
Pipeline Focus: Roche, through its Genentech division, focuses on oncology, neurology, and immunology biologics.
Notable Programs: Roche is a leader in Antibody-Drug Conjugates (ADCs), combining biologics with cytotoxic agents, where nanotechnology can enhance delivery. Roche is exploring nanoparticle formulations to improve the stability and delivery of Ocrevus for multiple sclerosis.
Sanofi
Pipeline Focus: Sanofi’s pipeline includes biologics for immunology, oncology, and rare diseases.
Notable Programs: Sanofi is expanding its use of biologics such as Dupixent in immunology, with nanotechnology playing a role in enhancing formulations.
Merck & Co.
Pipeline Focus: Merck’s pipeline includes biologics for oncology, infectious diseases, and vaccines.
Notable Programs: Merck is exploring nanotechnology to improve the delivery of Keytruda, especially in combination therapies. Merck is using nanobiotechnology in vaccine formulations to improve immune response and stability.
Johnson & Johnson (Janssen Pharmaceuticals)
Pipeline Focus: Janssen’s pipeline includes biologics for oncology, immunology, and neuroscience.
Notable Programs: Nanotechnology is being explored to improve delivery and reduce side effects of DARZALEX.
AstraZeneca
Pipeline Focus: AstraZeneca’s pipeline includes biologics for oncology, respiratory, and cardiovascular diseases.
Notable Programs: AstraZeneca is exploring nanoparticle-based delivery systems to improve the efficacy of Imfinzi in cancer therapy.
Gilead Sciences
Pipeline Focus: Gilead focuses on biologics for viral infections, oncology, and inflammatory diseases.
Notable Programs: Gilead is using nanotechnology to develop long-acting biologics for HIV and Hepatitis B infections.
BioNTech
Pipeline Focus: BioNTech specializes in mRNA-based biologics, including vaccines and cancer immunotherapies, using nanotechnology for delivery.
Notable Programs: BioNTech is advancing mRNA-based cancer vaccines, using lipid nanoparticles for targeted delivery.
Emerging Players and Startups in Nano-Biotechnology
Moderna: Focused on mRNA biologics, using lipid nanoparticles for delivery, particularly in vaccines and personalized cancer therapies.
Selecta Biosciences: Developing biologic therapies with nanoparticle-based immune tolerance platforms, targeting autoimmune diseases and rare conditions.
Alnylam Pharmaceuticals: Specializes in RNAi therapeutics, utilizing lipid nanoparticles for delivery in rare diseases and genetic disorders.
These industry leaders are actively incorporating nanobiotechnology into their pipelines, aiming to create innovative biologics with improved efficacy, safety, and targeting capabilities.
Artixio is a leading regulatory consultancy firm dedicated to guiding pharmaceutical and healthcare companies through complex regulatory landscapes. Our expert team provides comprehensive support in regulatory strategy, compliance, and submissions, ensuring our clients navigate global regulations with confidence and efficiency. Trust Artixio to streamline your path to market success. Contact Artixio at info@artixio.com today.
References:
Comments